Related Experiment Videos

[Plasma fibronectin level in patients with moyamoya disease]

O Sasaki1, R Tanaka, T Koike

  • 1Department of Neurosurgery, Niigata University, Japan.

No to Shinkei = Brain and Nerve
|November 1, 1987
PubMed

Insights

Patients with moyamoya disease show significantly elevated plasma fibronectin (FN) levels compared to healthy individuals. This finding suggests a potential role for fibronectin in the development of this rare cerebrovascular condition.

Area of Science:

  • Neurology
  • Biochemistry
  • Vascular Biology

Context:

  • Moyamoya disease is a progressive occlusive cerebrovascular disorder affecting the circle of Willis.
  • Pathology reveals fibrocellular intimal thickening, but etiology and mechanisms remain unclear.
  • Fibronectin (FN) is a glycoprotein involved in connective tissue formation under physiological and pathological conditions.

Purpose:

  • To investigate the relationship between plasma fibronectin levels and moyamoya disease.
  • To determine if plasma FN levels differ in moyamoya disease patients compared to controls.

Summary:

  • Plasma fibronectin levels were measured in 39 moyamoya disease patients, 39 healthy controls, and 39 atherosclerotic cerebrovascular disease patients.
  • Moyamoya disease patients exhibited significantly higher plasma FN levels (42.5 ± 7.9 mg/dl) than healthy subjects (33.9 ± 6.3 mg/dl, p < 0.001).
  • Levels were further examined in pediatric and adult subgroups of moyamoya disease patients.

Impact:

  • Elevated plasma fibronectin suggests its involvement in the pathogenesis of moyamoya disease.
  • This finding may offer new insights into the underlying mechanisms of intimal thickening.
  • Further research into fibronectin's role could lead to novel diagnostic or therapeutic strategies for moyamoya disease.

Related Concept Videos